Quarterly ResultMay 11, 2026, 04:15 PM
LENZ Therapeutics Q1 Revenue $1.9M; Net Loss $41.5M
AI Summary
LENZ Therapeutics reported Q1 2026 total revenue of $1.9 million, driven by $1.7 million in VIZZ product sales, a 19% increase over Q4 2025. The company recorded a net loss of $41.5 million due to significant planned launch investments in selling, general, and administrative expenses. LENZ also highlighted strong commercial progress with approximately 46,000 paid VIZZ prescriptions since launch, an expanded sales force, and international regulatory submissions and partnerships, maintaining a cash position of $258.4 million.
Key Highlights
- Q1 2026 total revenue was $1.9 million, including $1.7 million in VIZZ product sales.
- Net loss for Q1 2026 was $41.5 million, or $1.32 per share.
- Cash, cash equivalents, and marketable securities totaled $258.4 million as of March 31, 2026.
- Approximately 46,000 paid VIZZ prescriptions were filled from launch through Q1 2026.
- Expanded sales force from 88 to 117 territories, expected to be fully deployed by end of Q2 2026.
- Submitted Marketing Authorization Applications for VIZZ to the EMA and MHRA in Q1 2026.
- Secured an exclusive distribution agreement with Lunatus for the Middle East, receiving a $0.2 million upfront payment.